Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Pharmaceuticals (Basel)
2023 May 07;165:. doi: 10.3390/ph16050707.
Show Gene links
Show Anatomy links
High Selectivity of 8-Hydroxyquinoline on Leishmania (Leishmania) and Leishmania (Viannia) Species Correlates with a Potent Therapeutic Activity In Vivo.
Lima SKS
,
Jesus JA
,
Raminelli C
,
Laurenti MD
,
Passero LFD
.
???displayArticle.abstract???
Leishmaniasis is a neglected disease caused by protozoa of the genus Leishmania, which causes different clinical manifestations. Drugs currently used in the treatment such as pentavalent antimonial and amphotericin B cause severe side effects in patients, and parasite resistance has been reported. Thus, it is necessary and urgent to characterize new and effective alternative drugs to replace the current chemotherapy of leishmaniasis. In this regard, it has been experimentally demonstrated that quinoline derivatives present significative pharmacological and parasitic properties. Thus, the aim of this work was to demonstrate the leishmanicidal activity of 8-hydroxyquinoline (8-HQ) in vitro and in vivo. The leishmanicidal activity (in vitro) of 8-HQ was assayed on promastigote and intracellular amastigote forms of L. (L.) amazonensis, L. (L.) infantum chagasi, L. (V.) guyanensis L. (V.) naiffi, L. (V.) lainsoni, and L. (V.) shawi. Additionally, the levels of nitric oxide and hydrogen peroxide were analyzed. The therapeutic potential of 8-HQ was analyzed in BALB/c mice infected with a strain of L. (L.) amazonensis that causes anergic cutaneous diffuse leishmaniasis. In vitro data showed that at 24 and 72 h, 8-HQ eliminated promastigote and intracellular amastigote forms of all studied species and this effect may be potentialized by nitric oxide. Furthermore, 8-HQ was more selective than miltefosine. Infected animals treated with 8-HQ by the intralesional route dramatically reduced the number of tissue parasites in the skin, and it was associated with an increase in IFN-γ and decrease in IL-4, which correlated with a reduction in inflammatory reaction in the skin. These results strongly support the idea that 8-HQ is an alternative molecule that can be employed in the treatment of leishmaniasis, given its selectivity and multispectral action in parasites from the Leishmania genus.
Adriana Jesus,
Leishmanicidal Activity and Ultrastructural Changes of Maslinic Acid Isolated from Hyptidendron canum.
2021, Pubmed
Adriana Jesus,
Leishmanicidal Activity and Ultrastructural Changes of Maslinic Acid Isolated from Hyptidendron canum.
2021,
Pubmed
Allam,
In vivo schistosomicidal activity of three novels 8-hydroxyquinoline derivatives against adult and immature worms of Schistosoma mansoni.
2013,
Pubmed
Baiocco,
Molecular basis of antimony treatment in leishmaniasis.
2009,
Pubmed
Battista,
Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases.
2020,
Pubmed
Burza,
Leishmaniasis.
2018,
Pubmed
Campos,
In vitro infectivity of species of Leishmania (Viannia) responsible for American cutaneous leishmaniasis.
2008,
Pubmed
Chakravarty,
Current and emerging medications for the treatment of leishmaniasis.
2019,
Pubmed
Chanmol,
In vitro anti-Leishmania activity of 8-hydroxyquinoline and its synergistic effect with amphotericin B deoxycholate against Leishmania martiniquensis.
2022,
Pubmed
Coimbra,
Quinoline derivatives: Synthesis, leishmanicidal activity and involvement of mitochondrial oxidative stress as mechanism of action.
2016,
Pubmed
Costa Duarte,
An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
2016,
Pubmed
Dorlo,
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
2012,
Pubmed
Duarte,
Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
2016,
Pubmed
Frézard,
Pentavalent antimonials: new perspectives for old drugs.
2009,
Pubmed
Garza-Tovar,
An overview of the treatment of cutaneous leishmaniasis.
2020,
Pubmed
Ghatee,
The Geographical Distribution of Cutaneous Leishmaniasis Causative Agents in Iran and Its Neighboring Countries, A Review.
2020,
Pubmed
Ghorbani,
Leishmaniasis in humans: drug or vaccine therapy?
2018,
Pubmed
Gupta,
Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.
2021,
Pubmed
Gupta,
Insights of 8-hydroxyquinolines: A novel target in medicinal chemistry.
2021,
Pubmed
Gurel,
Cutaneous leishmaniasis: A great imitator.
2020,
Pubmed
Hamill,
Amphotericin B formulations: a comparative review of efficacy and toxicity.
2013,
Pubmed
Ilari,
Toward a Drug Against All Kinetoplastids: From LeishBox to Specific and Potent Trypanothione Reductase Inhibitors.
2018,
Pubmed
Jesus,
Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis.
2020,
Pubmed
Kadri,
The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection.
2014,
Pubmed
Kaushal,
Leishmania species: A narrative review on surface proteins with structural aspects involved in host-pathogen interaction.
2023,
Pubmed
Kaushik,
Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent.
2021,
Pubmed
Lage,
An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.
2016,
Pubmed
Laurenti,
Evaluation of systemic immunity in atypical cutaneous leishmaniasis caused by Leishmania (L.) infantum chagasi.
2022,
Pubmed
Lindoso,
Review of the current treatments for leishmaniases.
2012,
Pubmed
Mookerjee Basu,
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.
2006,
Pubmed
Mosimann,
Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review.
2018,
Pubmed
Mukbel,
Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide.
2007,
Pubmed
Oliveira,
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
2011,
Pubmed
Palić,
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.
2022,
Pubmed
Passero,
The Potential of Traditional Knowledge to Develop Effective Medicines for the Treatment of Leishmaniasis.
2021,
Pubmed
Passero,
Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation.
2012,
Pubmed
Pippi,
8-Hydroxyquinoline-5-sulfonamides are promising antifungal candidates for the topical treatment of dermatomycosis.
2020,
Pubmed
Ponte-Sucre,
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
2017,
Pubmed
Pradhan,
Treatment options for leishmaniasis.
2022,
Pubmed
Real,
Cell-to-cell transfer of Leishmania amazonensis amastigotes is mediated by immunomodulatory LAMP-rich parasitophorous extrusions.
2014,
Pubmed
Reithinger,
Cutaneous leishmaniasis.
2007,
Pubmed
Ribeiro Antinarelli,
Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.
2022,
Pubmed
Rodríguez-Serrato,
Immune response to Leishmania mexicana: the host-parasite relationship.
2020,
Pubmed
Saha,
Conundrums in leishmaniasis.
2021,
Pubmed
Silva,
Synthesis, leishmanicidal activity, structural descriptors and structure-activity relationship of quinoline derivatives.
2018,
Pubmed
,
Echinobase
Silveira,
Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.
2009,
Pubmed
Silveira,
What makes mucosal and anergic diffuse cutaneous leishmaniases so clinically and immunopathogically different? A review in Brazil.
2019,
Pubmed
Sousa-Franco,
Infection-induced respiratory burst in BALB/c macrophages kills Leishmania guyanensis amastigotes through apoptosis: possible involvement in resistance to cutaneous leishmaniasis.
2006,
Pubmed
Srivastava,
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
2017,
Pubmed
Sundar,
Antimony toxicity.
2010,
Pubmed
Sundar,
Emerging therapeutic targets for treatment of leishmaniasis.
2018,
Pubmed
Taslimi,
Leishmaniasis and various immunotherapeutic approaches.
2018,
Pubmed
Tavares,
A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
2019,
Pubmed
Tavares,
Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species.
2018,
Pubmed
Tavares,
A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model.
2020,
Pubmed
Torres Suarez,
Antileishmanial activity of synthetic analogs of the naturally occurring quinolone alkaloid N-methyl-8-methoxyflindersin.
2020,
Pubmed
Yamamoto,
Tolnaftate inhibits ergosterol production and impacts cell viability of Leishmania sp.
2020,
Pubmed
de Melo,
Challenges in the therapy of visceral leishmaniasis in Brazil: a public health perspective.
2013,
Pubmed
van Griensven,
Visceral leishmaniasis.
2012,
Pubmed
van Griensven,
Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens.
2019,
Pubmed